Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia

World Journal of Biological Psychiatry

Volumn 12, Issue 8, 2011, Pages 588-597

  Michel, Tanja Maria ^a,b   Sheldrick, Abigail Jane ^a   Camara, Sybille ^b   Grnblatt, Edna ^b   Schneider, Frank ^a   Riederer, Peter ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Free radicals; Oxidative stress; Prooxidants; Psychosis; Schizophrenia; Xanthine oxidase

Indexed keywords

ADENOSINE; CHLORPROMAZINE; CHLORPROTHIXENE; FREE RADICAL; HALOPERIDOL; OXIDIZING AGENT; PURINE; THIORIDAZINE; XANTHINE OXIDASE;

AGED; ARTICLE; AUTOPSY; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MENTAL DISEASE; OCCIPITAL CORTEX; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PSYCHOSIS; PUTAMEN; SCHIZOPHRENIA; TEMPORAL CORTEX; THALAMUS;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCIPITAL LOBE; OXIDATIVE STRESS; SCHIZOPHRENIA; THALAMUS; XANTHINE OXIDASE;

EID: 82955246786     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.526146     Document Type: Article

References (79)

1. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, et al. 1999. Vitamin E treatment for tardive dyskinesia. Arch J Psychiatry 56:836-841. (Pubitemid 29420705)
2. Akhondzadeh S, Safarcherati A, Amini H. 2005. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 29:253-259. (Pubitemid 40202911)
3. Akyol O, Herken H, Uz E, Fadillioǧlu E, Unal S, Söǧüt S, et al. 2002. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 26:995-1005. (Pubitemid 35245568)
4. Akyol O, Yanik M, Elyas H, Namli M, Canatan H, Akin H, et al. 2005. Association between Ala-9Val polymorphism of Mn-SOD gene and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 29:123-131. (Pubitemid 40018214)
5. Ames BN, Cathcart R, Schwiers E, Hochstein P. 1981. Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA 78:6858-6862. (Pubitemid 12216861)
6. Auer DP, Wilke M, Grabner A, Heidenreich JO, Bronisch T, Wetter TC. 2001. Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1 H-MRS and tissue segmentation. Schizophr Res 52:87-99. (Pubitemid 32947051)
7. Bowmann GL, Shannon J, Frei B, Kaye JA, Quinn JF. 2010. Uric acid as a CNS antioxidant. J Alzheimers Dis 19:1331-1336.
8. Brunstein MG, Ghisolfi ES, Ramos FL, Lara DR. 2005. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J Clin Psychiatry 66:213-219. (Pubitemid 40314328)
9. Buie LW, Oertel MD, Cala SO. 2006. Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia. Ann Pharmacother 40:2200-2204. (Pubitemid 44954440)
10. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, et al. 2003. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 5:443-456 (Pubitemid 36539053)
11. Deckert J, Brenner M, Durany N, Zöchling R, Paulus W, Ransmayr G, et al. 2003. Upregulation of striatal adenosine A (2A) receptors in schizophrenia NeuroReport 3:313-316. (Pubitemid 36337921)
12. Deicken RF, Johnson C, Eliaz Y, Schuff N. 2000. Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. Am J Psychiatry 157:644-647. (Pubitemid 30191210)
13. Dickerson FB, Stallings CR, Origoni AE, Sullens A, Khushalani S, Sandson N, Yolken RH. 2009. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophr Res 9:66-69.
14. Durany N, Muench G, Michel T, Riederer P. 1999. Investigations on oxidative tress and therapeutical imlications in dementia. Eur Arch Psychiatry Clin Neurosci 249:68-73.
15. Durany N, Michel T, Jellinger K, Cruz-Sanchez FF, Cervos-Navarro J, Riederer P. 2000. Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Dev Neurosci 18:807-881.
16. Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P, Thome J, 2001. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 52:79-86. (Pubitemid 32947050)
17. Ellison-Wright I, Bullmore E. 2009. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res 108:3-10.
18. Ende G, Braus DF, Walter S, Henn FA. 2005. Lower concentrations of thalamic NAA in patients with schizophrenia: a replication study. Am J Psychiatry 158:1314-1316. (Pubitemid 32717708)
19. Ettinger U, Kumari V, Collier DA, Powell J, Luzi S, Michel TM, et al. 2008. Catechol-O-Methyltransferase (COMT) Val (158) Met genotype is associated with BOLD response as a function of task characteristic. Neuropsychopharmacology 13:3046-3057.
20. Ettinger U, Williams SC, Patel D, Michel TM, Nwaigwe A, Caceres A, et al. 2009. Effects of acute nicotine on brain function in healthy smokers and non-smokers: estimation of interindividual response heterogeneity. Neuroimage 45:549-561.
21. Grünblatt E, Schlosser R, Fischer P, Fischer MO, Li J, Koutsilieri E, et al. 2005. Oxidative stress related markers in the 'VITA' and the centenarian projects. Neurobiol Aging 26:429-438. (Pubitemid 40093926)
22. Grünblatt E, Monoranu CM, Apfelbacher M, Keller D, Michel TM, Alafuzoff I, et al. 2009. Tryptophan is a marker of human postmortem brain tissue quality. J Neurochem 110:1400-1408.
23. Gsell W, Lange KW, Pfeuffer R, Heckers S, Heinsen H, Jellinger K, et al. 1993. How to run a brain bank. A report from the Austro-German brain bank. J Neural Transm Suppl 39:31-70. (Pubitemid 23216927)
24. Hartberg CB, Lawyer G, Nyman H, Jönsson EG, Haukvik UK, Saetre P, et al. 2010. Investigating relationships between cortical thickness and cognitive performance in patients with schizophrenia and healthy adults. Psychiatry Res 182:123-133.
25. Harrison R. 2002. Structure and function of xanthine oxidoreductase: Where are we now? Free Radic Biol Med 33:774-797. (Pubitemid 35232313)
26. Herken H, Uz E, Ozyurt H, Söǧüt S, Virit O, Akyol O. 2001. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatry 6:66-73. (Pubitemid 32096067)
27. Jakary A, Voinogradov S, Feiwell R, Deicken RF. 2005. NAA reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume corrected proton MRSI. Schizophr Res 76:173-185. (Pubitemid 40804764)
28. Kristal BS, Krasnikow BF. 2003. Structure-(Dys) function relationships in mitochondrial electron transport chain. Sci Aging Knowledge Enivon Feb. 5: PE3.
29. Kristall BS, Vigneau-Callahan KE, Moskowitz AJ, Matson WR. 1999. Purine catabolism: Links to mitochondrial respiration and antioxidant defenses? Arch Biochem Biophys 370:22-33. (Pubitemid 29476946)
30. Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, et al. 2005. Oxidative stress during treatment with first-and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci 17:227-231. (Pubitemid 41350611)
31. Lara DR, Brunstein MG, Ghisolfi ES, Lobato MI, Belmontede-Abreu P, Souza DO. 2001. Allopurinol augmentation for poorly responsive schizophrenia. Int Clin Psychopharmacol 16:235-237. (Pubitemid 32612522)
32. Lara DR, Dall'Igna OP, Ghisolfi ES, Brunstein MG. 2006. Involvment of adenosine in the neurobiology of schizophrenia an its therapeutic implications. Prog Neuro-Psychopharmacol Biol Psychiatry 30:617-629.
33. Lohr JB, Cligiuri MP. 1996. A double-blind placebo controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 57:167-173. (Pubitemid 26123363)
34. Mahadik SP, Evans DR. 2003. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr Clin North Am 26:85-102 (Review). (Pubitemid 36384349)
35. Mahadik SP, Gowda S. 1996. Antioxidants in the treatment of schizophrenia. Drugs Today 32:1-13.
36. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, et al. 2008. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1 H-MRS study. PLoS One 3:e1944.
37. Maier CM, Chan PK. 2002. Role of superoxide dismutases in oxidative damage in neurodegenerative disorders. Neuroscientist 8:323-334. (Pubitemid 34824016)
38. Miao B, Yin XH, Pei DS. 2005. Neuroprotective effects of preconditioning ischemia on ischemic brain injury through down-regulating activation of JNK1/2 via N-methyl-D-aspartate receptor-mediated Akt1 activation. J Biol Chem 280:21693-21699. (Pubitemid 40827815)
39. Michel TM, Thome J, Nara K, Martin D, Camara S, Weijers HG, et al. 2004. The role of oxidative stress in the pathogenesis of schizophrenic psychoses: superoxide dismutase (SOD) - coenzyme con-centrations in post-mortem brain tissue of schizophrenic patients. J Neural Transm 111:1191-1201.
40. Michel TM, Frangou S, Thiemeyer D, Camara S, Zoechling R, Jecel J, et al. 2007. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder-a postmortem study. Psychiatry Res 15:145-150. (Pubitemid 46634625)
41. Michel TM, Frangou S, Camara S, Tatschner T, Sheldrick AJ, Riederer P, Grünblatt E. 2008a. Evidence for increased oxidative stress in the thalamus and in the putamen in patients with recurrent depressive disorder-a post-mortem investigation. World J Biol Psychiatry 12:1-7.
42. Michel TM, Vieten A, Sahlmann M, Weis J, Krüttgen A, Sheldrick A, et al. 2008b. The development of schizophrenic Psychosis. Disturbance of neuronal plasticity inbetween oxidative stress and neurotrophic factors. (Die Entstehung schizophrener Psychosen-Störung neuronaler Plastizität im Spannungsfeld zwischen oxidativem Stress und Nervenwachstumsfaktoren.) Nervenarzt Suppl 4:477.
43. Michel TM, Gsell W, Käsbauer L, Zöchling T, Sheldrick AJ, Neuner I, et al. 2010a. Increased activity of mitochondrial aldehyde dehydrogenase (ALDH) activity in the putamen of individuals with Alzheimer's disease-a preliminary human post-mortem study. J Alzheimer's Dis 19:1295-1301.
44. Michel TM, Gsell W, Geuder J, Frangou S, Durany N, Kircher T, et al. 2010b. Can enzyme kinetics of prooxidants teach us a lesson about the treatment of Alzheimer's disease-A pilot-post-mortem study. World J Biol Psychiatry 11:677-681.
45. Monoranu CM, Grünblatt E, Bartl J, Meyer A, Apfelbacher M, Keller D, et al. 2010. Methyl-und acetyltransferase are stable epigenetic markers post-mortem. Cell Tissue Bank (Epub ahead of print July 23).
46. Nickl-Jockschat T, Michel TM. 2010a. Genetic and brain structure anomalies in autism spectrum disorders: Towards an understanding of the aetiopathogenesis? Nervenarzt (Epub ahead of print April 22).
47. Nickl-Jockschat T, Michel TM. 2010b. Neurotrophic factors in autisms spectrum disorders. Molecular Psychiatry. Mol Psychiatry (Epub ahead of print October 12).
48. Othmen LB, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, et al. 2008. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuropsychopharmacol Biol Psychiatry 32:155-159.
49. Ozyurt B, Ozyurt H, Akpolat N, Erdogan H, Sarsilmaz M. 2007. Oxidative stress in prefrontal cortex of rat exposed to MK-801 and protective effects of CAPE. Prog Neuropsychopharmacol Biol Psychiatry 31:832-838. (Pubitemid 46660297)
50. Parikh V, Khan MM, Mahadik SP. 2003. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 37:43-51. (Pubitemid 35449770)
51. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, et al. 2008. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9:684-697.
52. Preisig M, Saraga M. 2006. Schizophrenia and oxidative stress-glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 79:586-592. (Pubitemid 44384270)
53. Premkumar P, Cooke MA, Fannon D, Peters E, Michel TM, Aasen I, et al. 2008. Misattribution biases of threat-related facial expressions are related to a longer duration of illness and a cognitive deficit syndrome in schizophrenia. Eur Psychiatry 23:14-19.
54. Qiu A, Ruan TA, Woon PS, Abdul-Rahman MF, Graham S, Sim K. 2010. Hippocampal-cortical structural connectivity dis ruptions in schizophrenia: An integrate perspective from hippocampal shape, cortical thickness, and integrity of white matter bundles. Neuroimage 2010. 52:1181-9.
55. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, et al. 2003. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 121:109-122. (Pubitemid 37500981)
56. Reddy R, Ya o J. 1996. Free radical pathology in schizophrenia: a review. Prostagladins Leukotrienes Essent. Fatty Acids 55:33-43. (Pubitemid 26321116)
57. Reddy RD, Keshavan MS, Yao JK. 2003. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr Res 62:205-212. (Pubitemid 36773929)
58. Sahlmann M, Vieten A, Sheldrick AJ, Haeck M, Schneider F, Michel TM. 2010. Early recognition centres for patients at risk of developing schizophrenia in Germany. (Früherkennung und Frühbehandlung von Patienten mit erhöhtem Schizophrenierisiko in Deutschland.) Gesundheitsfürsorge (Epub ahead of print January 4) doi: 10.1055/s-0029-1242783.
59. Singh OP, Chakraborty I, Dasgupta A, Datta S. 2008. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J Psychiatry 50:171-176.
60. Sheldrick AJ, Krug A, Markov V, Leube D, Michel TM, Zerres K, Kircher T. 2008. Effect of COMT val158met genotype on cognition and personality traits. Eur Psychiatry 23:413-420.
61. Shriqui CL, Bradjewejn J, Annabel L, Jones BD. 1992. Vitamin E in the treatment of tardive dyskinesia; a double-blind placebocontrolled study. Am J Psychiatry 149:391-393.
62. Shenton ME, Dickey CC, Frumin M, McCarley RW. 2001. A review of MRI findings in schizophrenia. Schizophr Res 1-2:1-52. (Pubitemid 32451739)
63. Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandöl E. 2007. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 31:1493-1499. (Pubitemid 47302571)
64. Stöber G, Ben-Shachar D, Cardon M, Falkai P, Fonteh AN, Gawlik M, et al. 2009. Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry 10:127-155.
65. Suzuki S, Kaneko M, Chapman DC, Dhalla NS. 1996. Alterations in cardiac contractile proteins due to oxygen free radicals Biochim Biophys Acta 1074:95-100.
66. Taneli F, Pirildar S, Akdeniz F, Uyanik BS, Ari Z. 2004. Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res 35:401-405. (Pubitemid 40018180)
67. Thome J, Nara K, Foley P, Michel T, Gsell W, Retz W, et al. 1997. CNTF genotypes: infl uence on choline acetyltransferase (ChAT) and acetylcholine esterase (AChE) activities and neurotrophin 3 (NT3) concentration in human post mortem brain tissue. J Brain Res 38:443-451. (Pubitemid 127497699)
68. Turner CP, Pulciani D, Rivkees SA. 2002. Aq adenosine receptor activation incduces ventriculomegaly and white matter loss. NeuroReport 9:1199-1204. (Pubitemid 34722053)
69. Virit O, Altindag A, Yumru M, Dalkilic A, Savas HA, et al. 2009. A defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 60:87-93.
70. Wiesbeck GA, Weijers HG, Wodarz N, Hermann M, Johann M, Keller H, et al. 2003. Dopamin D 2 (DAD 2) and dopamin D 3 (DAD 3) receptor gene polymorphismus and treatment outcome in alcohol dependence. J Neural Transm 110:813-820. (Pubitemid 36783234)
71. WHO. 1992. International Classification of Diseases. Geneva: WHO.
72. Yao JK, Reddy R, van Kammen DP. 1998. Reduced level of plasma antioxidant uric acid in schizophrenia. Psychiatry Res 80:29-39. (Pubitemid 28370837)
73. Yao JK, Reddy RD, van Kammen DP. 2001. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 45:1512-1515.
74. Yao JK, Leonard S, Reddy RD. 2004. Increased nitric oxide radicals in post-mortem brain from patients with schizophrenia. Schizophr Bull 30:923-934. (Pubitemid 40469526)
75. Yao JK, Leonard S, Reddy RD. 2006. Altered glutathione redox state in schizophrenia. Dis Markers 22:83-93. (Pubitemid 41831607)
76. Yoon JH, Maddock RJ, Rokem A, Silver MA, Minzenberg MJ, Ragland JD, Carter CS. 2010. GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression. J Neurosci 30:3777-3781.
77. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY. 2003. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res 117:85-88. (Pubitemid 36173777)
78. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y. 2006. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 81:291-300. (Pubitemid 43107705)
79. Zhang XY, Zhou DF, Qi LY, Chen S, Cao LY, Chen C, et al. 2009. Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics. Psychopharmacology (Berlin) 204:177-184.